[Skip to Content]
[Skip to Content Landing]
Article
September 1984

Clinical Trials and the Practice of Ophthalmology

Arch Ophthalmol. 1984;102(9):1282-1285. doi:10.1001/archopht.1984.01040031032018

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

In recent years, ophthalmologists have grown accustomed to clinical trials that demonstrate therapeutic benefit. The first major eye trial in recent years was the Diabetic Retinopathy Study,1 which reported in 1976 that scatter laser photocoagulation was effective in reducing the risk of loss of vision in eyes with proliferative retinopathy. In 1982, the Macular Photocoagulation Study (MPS) Group2 announced that prompt argon laser photocoagulation of neovascular membranes (NVMs) outside the foveal avascular zone (FAZ) reduced the risk of severe loss of vision in patients with age-related macular degeneration (AMD).

See also p 1299.

In 1983, the MPS Group3 reported similar findings for treatment of eyes with ocular histoplasmosis and new vessels outside the FAZ. Also in 1983, the Proliferative Sickle Cell Retinopathy Trial4 reported that feeder vessel photocoagulation reduced the incidence of vitreous hemorrhage and subsequent loss of vision, and the Central Serous Chorioretinopathy Trial5

References
1.
Diabetic Retinopathy Study Research Group:  Preliminary report on effects of photocoagulation therapy . Am J Ophthalmol 1976;81:383-396.
2.
Macular Photocoagulation Study Group:  Argon laser photocoagulation for senile macular degeneration: Results of a randomized clinical trial . Arch Ophthalmol 1982;100:912-918.Article
3.
Macular Photocoagulation Study Group:  Argon laser photocoagulation for ocular histoplasmosis: Results of a randomized clinical trial . Arch Ophthalmol 1983;101:1347-1357.Article
4.
Jampol LM, Condon P, Farber M, et al:  A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy: I. Preliminary results . Ophthalmology 1983;90:540-545.Article
5.
Robertson DM, Ilstrup D:  Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy . Am J Ophthalmol 1983;95:457-466.
6.
Coronary Drug Project Research Group:  Practical aspects of decision making in clinical trials: The Coronary Drug Project as a case study . Controlled Clin Trials 1981;1:363-376.Article
7.
Multiple Risk Factor Intervention Trial Research Group:  Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results . JAMA 1982;248:1465-1477.Article
8.
CASS Principal Investigators and Their Associates:  Myocardial infarction and mortality in the Coronary Artery Surgery Study (CASS) Randomized Trial . N Engl J Med 1984;310:750-758.Article
9.
Moorfields Macular Study Group:  Retinal pigment epithelial detachment in the elderly: A controlled trial of argon laser photocoagulation . Br J Ophthalmol 1982;66:1-16.Article
10.
Bird AC:  Macular disciform response and laser treatment . Trans Ophthalmol Soc UK 1977;97:490-493.
11.
Patz A, Hoeck LE, de la Cruz E:  Studies on the effect of high oxygen administration in retrolental fibroplasia: I. Nursery observations . Am J Ophthalmol 1952;35:1248-1253.
12.
Bressler SB, Bressler NJ, Fine SL, et al:  Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration . Am J Ophthalmol 1982; 93:157-163.
13.
Jalkh AE, Avila MP, Trempe CL, et al:  Management of choroidal neovascularization within the foveal avascular zone in senile macular degeneration . Am J Ophthalmology 1983;95:818-825.Article
×